Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that it has been granted a patent on its Bio-RFID technology. The issued patent is broad, covering the platform nature of the Bio-RFID technology and health related diagnostics employing spectroscopy in the radio/microwave frequency band.
Phil Bosua, Know Labs CEO and inventor of the Bio-RFID technology, said, “We are extremely pleased and proud to obtain this patent. It is truly an invention which we believe can disrupt and revolutionize non-invasive human biomarker detection and medical diagnostics.”
Bio-RFID technology uses radio and microwave frequencies in new ways. Nikola Tesla was quoted saying, “If you want to find the secrets of the universe, think in terms of energy, frequency and vibration.” Bio-RFID unlocks some of these secrets.
Know Labs’ first focus with its Bio-RFID technology is the wearable non-invasive continuous monitoring of blood glucose levels, an important breakthrough for the diabetes community. The Company is making rapid progress engineering the UBAND Continuous Glucose Monitor (CGM) into its market ready form for clinical trials later this year, the results of which will be submitted to the US Food and Drug Administration for approval.
As a platform technology, the monitoring of blood glucose is the first of many diagnostics Know Labs will pursue. The Company has developed a long list of other molecules that are important diagnostic markers of human health and wellness.
Dr. James “Andy” Anderson, Know Labs Chief Medical Officer and highly regarded leader in diabetes and epidemiology, stated, “This is an exciting and extremely significant patent for health care. The Bio-RFID technology is performing in the laboratory with increasing accuracy and precision as it continuously monitors blood glucose levels. Non-invasive glucose monitoring for the diabetes and pre-diabetes community is our first focus. Over time we will identify many indicators of disease, leading one day, I believe, to our ability to provide an early warning detection system for some types of cancer, markers of developing diseases, and even viruses and the health conditions that make us vulnerable to pandemics like the one we are facing today.”
The patent, issued by the United States Patent and Trademark Office as US Patent No. 10,548,503 B2, is entitled “Health Related Diagnostics Employing Spectroscopy in Radio/Microwave Frequency Band.” This newly issued patent continues the expansion of the Know Labs intellectual property portfolio. The Company continues to have a significant number of patents pending and aggressively works to expand the reach of its Bio-RFID and related electromagnetic technology. A copy of the patent may be found at www.uspto.gov.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct radio waves or structured light through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. It is used to identify, detect, or diagnose substance markers, molecules or biomarkers. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Those wishing to stay up to date on the developments at Know Labs can subscribe to the Company’s YouTube channel at this link. For more information on Know Labs, visit the company’s website at www.knowlabs.co.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2018, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.